HIV-VAC, Inc. Aids Vaccine Could be Powerful Weapon To Combat Global Aids Crisis.

Business Editors, Medical Writers

TORONTO--(BUSINESS WIRE)--May 2, 2000

White House Says AIDS is National Security Threat: National

Security Council Budgets $254 Million to Combat AIDS Overseas

HIV-VAC, Inc., (OTC/BB: HIVC) stated today that the Company's AIDS vaccine could become a powerful tool to help combat the global AIDS crisis. Sandy Thurman, who heads up President Clinton's Office of National AIDS Policy, said that "we are just at the beginning of a pandemic, the likes of which we have not seen in this century, and in the end, will probably never have seen in history."

The National Security Council, which has never had to combat an infectious disease as a national threat, is directing a $254 million government effort to combat AIDS on a global basis. In a recent National Intelligence Estimate, U.S. government analysts projected that a quarter of the sub-Saharan population of Africa is likely to die of AIDS, and, based on current trends, the same fate faces south Asia, Eastern Europe and the former Soviet Union. According to the study, demographic catastrophe will occur in sub-Saharan Africa, and later in other regions over the next 20 years, leading to revolutionary wars, ethnic wars, genocide and disruptive regime transitions.

HIV-VAC, Inc.'s Skinner AIDS vaccine has the potential to prevent AIDS, and also may prevent the onset of AIDS in HIV positive patients.

The Skinner HIV-VAC AIDS vaccine is based on a new and very unique approach to neutralizing the AIDS virus. Unlike many other AIDS vaccines under development, the Company believes that the Skinner vaccine has the potential to be effective with the AIDS virus' many mutant forms. This technology is based on a unique intracellular vaccine technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines. This has been under development by Dr. Skinner and his team for the past 10 years at the University of Birmingham, United Kingdom.

The United Nations estimates that there are currently 33.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million. Sales of anti-HIV drugs increased to more than $3 billion last year and could reach $6 billion in coming years.

HIV-VAC, Inc. supporting the efforts of the National AIDS Vaccine Advocacy Project (NAVAP) to focus attention on the need for AIDS vaccine research and development.

The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.